Ticker Details
Xencor, Inc. Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers.
IPO Date:	December 3, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$838.54M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.55 | 2.34%
Avg Daily Range (30 D):	$0.35 | 2.89%
Avg Daily Range (90 D):	$0.36 | 2.96%

Institutional Daily Volume
Avg Daily Volume:	.29M
Avg Daily Volume (30 D):	.6M
Avg Daily Volume (90 D):	.58M

Trade Size
Avg Trade Size (Sh.):	68
Avg Trade Size (Sh.) (30 D):	48
Avg Trade Size (Sh.) (90 D):	55

Institutional Trades
Total Institutional Trades:	3,297
Avg Institutional Trade:	$1.98M
Avg Institutional Trade (30 D):	$1.55M
Avg Institutional Trade (90 D):	$1.7M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.24M
Avg Closing Trade (30 D):	$1.6M
Avg Closing Trade (90 D):	$1.78M
Avg Closing Volume:	92.86K

News

Feb 18, 2026 @ 4:00 PM CTLA-4 Inhibitors Competitive Landscape Research R... Source: Researchandmarkets.Com

Jan 14, 2026 @ 8:30 AM [Latest] Global T-Cell Engagers Market Size/Share ... Source: Custom Market Insights

Aug 6, 2025 @ 8:13 PM Xencor (XNCR) Q2 Revenue Jumps 82% Source: Not Specified

Jul 16, 2025 @ 4:30 AM [Latest] Global Ultomiris Drug Market Size/Share W... Source: Custom Market Insights

Sep 12, 2024 @ 5:09 PM Xencor Surges 10.5%: Is This an Indication of Furt... Source: Zacks

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-2.29	$-1.71	$-.09
Diluted EPS	$-2.29	$-1.71	$-.09
Revenue	$97.36M	$4.52M	$28.24M
Gross Profit
Net Income / Loss	$-172.42M	$-128.92M	$-6.65M
Operating Income / Loss	$-212.18M	$-77.86M	$-53.63M
Cost of Revenue
Net Cash Flow	$-25.6M	$-40M	$25.78M
PE Ratio